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Background/aim: To evaluate total oxidant status (TOS), total antioxidant capacity (TAC), and paraoxonase 1 (PON1) levels in children
with noncystic fibrosis (CF) bronchiectasis (BE), and to compare these levels with those of healthy controls. The study parameters were
also evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions.
Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1
levels were determined. Lung function tests were performed by spirometry.
Results: Serum TOS was higher in the patients [median 9.54 (IQR 25–75 = 7.05–13.30) µmol H2O2 Eq/L] than in the healthy subjects
[6.64 (5.45–9.53) µmol H2O2 Eq/L] (P < 0.001). TAC was higher in patients with non-CF BE [1.07 (1.0–1.07) mmol Trolox Eq/L] than
in the healthy controls [0.87 (0.77–0.98) mmol Trolox Eq/L] (P < 0.001). In addition, serum PON1 levels were significantly higher in
the patients [106.5 (42.5–154.2) U/L] than in the controls [47.7 (27.5–82.1) U/L] (P < 0.001). The patients with low FEV1 had decreased
TAC when compared to those who had normal FEV1 in non-CF BE.
Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidative
status, antioxidant defenses parameters, and PON1 values.
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1. Introduction
Bronchiectasis (BE) is a chronic airway disease
characterized by abnormal destruction and dilatation of
the large airways, bronchi, and bronchioles. Its etiologies
include cystic fibrosis (CF), primary ciliary dyskinesia
(PCD), genetic abnormalities, immune deficiency
syndromes, altered host defense and autoimmune diseases,
severe infections, and acquired disorders. The underlying
cause of BE may be impossible to identify in about 50% of
cases (1).
In BE, airways are progressively damaged as a result
of the interplay between chronic microbial infection,
airway inflammation, and tissue-damaging substances
secreted by neutrophils, eosinophils, macrophages, and
epithelial cells, all of which produce proteinase enzymes
and reactive oxygen radicals (2). These radicals interact
with various cellular components and macromolecules,
and cause metabolic, structural, and functional damage
that may lead to cell death (3). During a respiratory

burst, excessive quantities of free radicals overwhelm host
antioxidant defenses, which then also cause severe damage
to the airway epithelial cells and other airway structures
(4). When the production of damaging oxidative stress
exceeds the capacity of the body’s antioxidant defenses to
detoxify it, this condition is known as oxidative stress (5).
Paraoxonase1 (PON1) is one of the important enzymatic
antioxidants synthesized by the liver (6). Previous studies
have shown that PON1 is an independent risk factor for
cardiovascular disease (7); however, the exact antioxidant
mechanism of PON1 is not yet known. It is thought that
cell damage caused by free oxygen radicals contributes
to the pathogens of several chronic respiratory diseases,
including asthma, chronic obstructive lung disease, and
CF (3,8–11). Only one study touched on oxidative stress in
adult patients with BE (12).
Studies have separately measured serum concentrations
of oxidants and antioxidants in laboratories, but
the methods used are time-consuming and require
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complicated techniques (13). New methods to measure
total oxidant status (TOS) and total antioxidant capacity
(TAC) are rapid, reliable, and inexpensive (14,15). No
study in the literature reports having measured the levels
of TOS, TAC, and PON1 in pediatric patients with nonCF BE.
The present study investigated the serum TOS, TAC,
and PON1 levels in pediatric patients with non-CF BE and
compared them with those of healthy controls. In addition,
we evaluated the study parameters according to some
demographic, anthropometric, and clinical characteristics,
as well as lung function tests.
2. Methods
2.1. Study design and patients
The required sample size was 65 participants for each
group according to the power analysis (power = 0.8 at
α = 0.05). Enrolled in this cross-sectional study were 68
healthy controls to compare with 118 pediatric patients
who were followed up with the diagnosis of non-CF BE in
the Pediatric Pulmonology Division of Bezmialem Vakıf
University Hospital from September 2010 to September
2013. The diagnosis of BE was based on standard criteria.
The most specific features are (a) the internal diameter of
a bronchus wider than its adjacent pulmonary artery, (b)
failure of the bronchi to taper, and (c) visualization of the
bronchi in the outer 1–2 cm of the lung field (16). High
resolution computed tomography (HRCT) was used in
all cases. Patients with CF were excluded from the study
by two negative measurements of sweat tests and negative
CFTR genetic mutation analysis (1).
A detailed disease history of each participant was
obtained from the parents. Each subject underwent a
complete physical examination and pulmonary function
test. During clinical visits, body height and weight were
measured using a standard stadiometer and a digital scale
so that age- and sex-specific body mass index (BMI) (kg/
m2) percentiles could be calculated.
Because a greater degree of chronic hypoxia can
contribute to greater oxidative stress, patients were
excluded who were not, during the month prior to the
study, in a clinically stable condition, for example by
having had respiratory exacerbation or a recent hospital
admission. Exacerbation was defined as deterioration
of respiratory symptoms, systemic disturbances and
radiographing deterioration, or need for hospitalization.
Also excluded were children taking dietary supplements
with vitamins or omega 3 fatty acids, or using immune
suppressive drugs such as systemic corticosteroids.
The control group consisted of age- and sex-matched
children who had been admitted to Bezmialem Vakıf
University pediatric outpatient clinic. None of the healthy
controls had malnutrition, immune deficiency, or history
of immunosuppressive drug use.
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2.2. Lung function testing
Lung function was measured by spirometry. Measurements
were performed using the Spirolab III (Medical
International Research, Italy) in patients over 6 years old.
Forced expiratory volume in the first second of expiration
(FEV1), forced vital capacity (FVC), and FEV1/FVC
were measured according to standard criteria (17). These
parameters were expressed as percent predicted values for
each patient’s age, height, and sex. Lung function values
<60% were classified as low, 60%–80% were mild, and
>80% were normal.
2.3. Blood sample collection and measurements of TOS,
TAC, and PON1 levels
The blood samples were collected from the participants
over 2 months (October–November 2013). The samples
were centrifuged at 3000 rpm for 10 min. The resultant
serum centrifuge was transferred to Eppendorf tubes, and
then immediately stored at –80 °C until analysis.
The TOS of serum was measured by using a novel
automated colorimetric measurement method developed
by Erel (Rel Assay Diagnostic, Turkey) (14). The color
intensity, which can be measured spectrophotometrically,
is related to the total amount of oxidant molecules present
in the sample. The results are expressed in terms of
micromolar hydrogen peroxide equivalent per liter (µmol
H2O2 Equivalent/Liter).
TAC was measured using a novel automated
colorimetric measurement method also developed by
Erel (Rel Assay Diagnostic, Turkey) (15). In this method,
the change in absorbance at 660 nm is related to the total
antioxidant level of the sample. The results are expressed
as micromolar Trolox equivalent per liter (µmol Trolox
Equivalent/Liter).
The paroxonase1 enzyme activity was measured by
using commercially available kits (Rel Assay Diagnostic,
Turkey) (18). Paroxonase1 activity was expressed as U/L
serum.
2.4. Statistical analysis
SPSS version 15.0 was used for analysis. All data were
entered into SPSS and evaluated. The numerical parameters
were described with the mean, median, and standard
deviation; distributions of the categorical measurements
were determined by frequencies and percentages. Due
to the high range of dissociations, the Mann–Whitney
U test was used to compare the levels of TOS, TAS, and
PON1 between the patient and control groups. Multiple
comparisons were made using Spearman’s correlation and
categorical data were evaluated using the chi-square test.
P < 0.05 was accepted as statistically significant.
2.5. Ethic committee approval
The study protocol was carried out in accordance with
the Helsinki Declaration as revised in 1989. Signed
informed consent forms were obtained from the families
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of all participants. Ethical approval was obtained from
the Bezmialem Vakıf University Local Research Ethics
Committee (Ethical approval number: 71306642/050–01–
04/95).
3. Results
Enrolled in the study were 118 children with non-CF
BE and 68 healthy controls. The age distributions of the
patients were 0–24 months (n = 9, 7.6%), 25–74 months
(n = 6, 5.1%), and ≥75 months (n = 103, 87.4%). No
statistically significant differences arose between the
patient and control groups as to age, sex, weight, or body
mass index (BMI) (Table 1).

Serum TOS (Figure 1) and TAC (Figure 2) were higher
in patients with non-CF BE than in the healthy subjects.
In addition, serum PON1 levels were significantly higher
among the patients than the controls (Figure 3). See the
results of study parameters in Table 2.
No correlation was found between study parameters
and demographic and anthropometric characteristics such
as age, sex, weight, and BMI (P > 0.05).
Spirometry was performed in 86 (72.9 %) of the
patients in order to examine the relationship between lung
function tests and the study parameters. The patients with
FEV1 < 60% had decreased TAC compared to those with
normal FEV1 (>80%) (P = 0.027). Patients’ FVC and FEV1/

Table 1. Comparison of demographical properties in children with non-CF bronchiectasis and controls.
Patients
(n = 118)

Controls
(n = 68)

Female

69 (58.5)

42 (61.8)

Male

49 (41.5)

26 (38.2)

Age (month) Mean ± SD (min–max)

127 ± 50 (9–192)

106.9 ± 40.7 (11–192)

P = 0.554

Weight, kg Mean ± SD (min–max)

38.5 ± 14.8 (6–78)

41.5 ± 15.1 (8–81)

P = 0.062

Height, cm Mean ± SD (min–max)

141.5 ± 20.6 (61–171)

143.1 ± 25.1 (68–180)

P = 0.091

BMI, kg /m2 Mean ± SD (min–max)

17.8 ± 3.55 (10.1–31)

17.7 ± 3.3 (9.92–28.7)

P = 0.983

Characteristics
Sex
(n, %)

P* Value
P = 0.07

* Pearson chi-square test was used for statistical analysis, P < 0.05

Figure 1. Comparison of total oxidant status between patients and control group.
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Figure 2. Comparison of total antioxidant capacity between patients and control group.

Figure 3. Comparison of paraoxonase 1 levels between patients and control group.

FVC ratio showed no statistically significant differences as
to TOS, TAS, or PON1 levels (P > 0.05) (Table 3).
4. Discussion
The current study demonstrated that the children with
non-CF BE had higher TOS, TAC, and PON1 levels, but no
correlation was found between these study parameters and
their demographic and anthropometric characteristics. In

4

addition, the patients with low FEV1 had decreased TAC
when compared with those who had normal FEV1.
Chronic pulmonary inflammation and infections
increase free radical production. The lungs’ advanced
antioxidant system functions to protect them from
exposure to harmful oxidants (19). Quantification of
oxidative stress can be assessed by the detection of lipid
peroxidation end-products derived from the degradation

GEDİK et al. / Turk J Med Sci
Table 2. Study parameters of the children with non-CF bronchiectasis and controls.
Parameters

Patients
Median (IQR 25–75)

Controls
Median (IQR 25–75)

P value

Total oxidant status (µmol H2O2 Eq/L)

9.54 (7.05–13.30)

6.64 (5.45–9.53)

P < 0.001

Total antioxidant capacity (µmol Trolox Eq/L)

1.07 (1.0–1.07)

0.87 (0.77–0.98)

P < 0.001

Paraoxonase 1 (U/L)

106.5 (42.5–154.2)

47.7 (27.5–82.1)

P < 0.001

* Mann–Whitney U test, P < 0.05

Table 3. The study parameters according to lung functions.

Predicted
values %

FEV1
Median (IQR 25–75)

FVC
Median (IQR 25–75)

FEV1/FVC
Median (IQR 25–75)

<80

60–80

<60

<80

60–80

<60

<80

60–80

<60

n, %

32 (37.2)

29 (33.7)

25 (29.1)

35 (40.7)

32 (37.2)

19 (22.1)

75 (87.2)

11 (12.8)

0

TOS

9.05
(6.3–13.1)

9.2
(5.9–13.1)

9.7
(7.5–11.6)

8.2
(5.4–10.6)

11.1
(7.0–14.6)

8.8
(7.4–10.8)

9.2
(6.7–12.5)

9.7
(7.4–13.0)

TAC*

1.04
(0.99–1.17)

1.18
(1.0–1.4)

1.07
(1.0–1.2)

1.1
(1.0–1.3)

1.1
(1.0–1.2)

1.1
(1.0–1.2)

1.1
(1.0–1.2)

1.1
(1.0–1.4)

PON1

126.1
(44.4–165.6)

65.8
(40.9–142.4)

120.2
(40.9–170.6)

120.2
(44.7–163.7)

95.5
(40.5–137.7)

135.9
(45.5–195.4)

120.0
(42.3–163.7)

96.0
(48.7–174.6)

* FEV1 < 60% had decreased TAC compared to those had normal FEV1 (>80%) (P=0.027).

of polyunsaturated fatty acids. Various markers for lipid
peroxidation are available and different detection methods
have been described in the literature (20). One of them is
a novel automated colorimetric measurement method for
TOS developed by Erel (14), who also developed another
such measurement method for TAC (15). His methodology
determines the antioxidative effect of the sample against
the potent free radical reactions initiated by the produced
hydroxyl radical. To the best of our knowledge, TOS, TAC,
and PON1 activity have not previously been investigated
in children with BE.
A lot of research suggests that oxidative stress
may contribute to the pathogenesis of many different
respiratory diseases, including CF, asthma, pulmonary
tuberculosis, and acute respiratory distress syndrome
(10,21–23). Lezo et al. demonstrated that the majority
of stable CF patients showed elevated oxidative stress
markers and plasma antioxidants within the normal range
(11). Similarly, Raghunath et al. found that the status of
oxidants in plasma levels increased significantly in adult
patients who had chronic obstructive pulmonary disease
and bronchial asthma (24).

Only one adult study demonstrated that plasma
markers of oxidative stress were raised in the adult patients
with BE, including those with CF, as compared with the
controls, and no differences were seen in the CF patients
compared with the other BE patients (25). In our study,
TOS and TAC were higher in children with non-CF BE
patients. Both chronic inflammation and infections in BE
may lead to increased TAC and TOS at the same time.
Similarly, some studies found that patients with asthma
and chronic tonsillitis had elevated levels of both TAC and
TOS (26,27).
Another parameter related to oxidative stress is serum
PON1 activity, which could be a key element responsible
for oxidative damage in the artery walls of humans.
Although some reports have partially investigated this
parameter in patients with cardiovascular disease, few
studies have evaluated serum PON1 activity in respiratory
diseases. Selek et al. showed that PON1 activity was
decreased in patients with pulmonary tuberculosis due
to reactive oxygen species pathogenesis under conditions
of oxidative stress and inflammation (22). Rumora et al.
reported that PON1 basal- and salt-stimulated PON1
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activity was significantly reduced in patients with chronic
obstructive pulmonary disease (28). Acar et al. found
that PON1 activity was lower in asthmatics and in COPD
than in controls, although no statistically significant
difference was found between the two groups (29). Our
study found higher PON1 levels. Increased PON1 levels
may be due to an impaired antioxidant defense system
in BE, which may indicate oxidative stress derived from
inflammation. Further studies are needed to clarify the
possible mechanisms underlying increased PON1 enzyme
activities.
We have shown that in patients with BE, TOS is
not associated with decline in pulmonary parameters;
however, the patients with decreased FEV1 had decreased
TAC levels compared to those with normal FEV1. This
may be explained by the impaired antioxidant capacity
relating to an increasing loss of pulmonary function as an

indicator of bronchiectasis severity. The limitation of the
current study was that the levels of study parameters were
detected from the serum of the patients instead of from
bronchoalveolar lavage fluid. However, the study was the
first study that reflected the levels of those parameters in
children with non-CF BE
In conclusion, this study demonstrates that, compared
with the control group, the children with non-CF BE had
elevated oxidative status, antioxidant defenses parameters,
and PON1 values. In addition, the patients with low
FEV1 had decreased TAC. Further studies are needed to
understand and explain the mechanisms of these study
parameters.
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